DE60231386D1 - Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson - Google Patents

Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Info

Publication number
DE60231386D1
DE60231386D1 DE60231386T DE60231386T DE60231386D1 DE 60231386 D1 DE60231386 D1 DE 60231386D1 DE 60231386 T DE60231386 T DE 60231386T DE 60231386 T DE60231386 T DE 60231386T DE 60231386 D1 DE60231386 D1 DE 60231386D1
Authority
DE
Germany
Prior art keywords
adenosine
treatment
compounds
combination
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231386T
Other languages
English (en)
Inventor
Dan Peters
Lars Christian Roenn
Karin Sandager Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Application granted granted Critical
Publication of DE60231386D1 publication Critical patent/DE60231386D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DE60231386T 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson Expired - Lifetime DE60231386D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100583 2001-04-09
PCT/DK2002/000228 WO2002080957A1 (en) 2001-04-09 2002-04-04 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DE60231386D1 true DE60231386D1 (de) 2009-04-16

Family

ID=8160425

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231386T Expired - Lifetime DE60231386D1 (de) 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Country Status (8)

Country Link
US (1) US7160899B2 (de)
EP (1) EP1379269B1 (de)
JP (1) JP2004529916A (de)
AT (1) ATE424194T1 (de)
CA (1) CA2440196A1 (de)
DE (1) DE60231386D1 (de)
MX (1) MXPA03009185A (de)
WO (1) WO2002080957A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4910500A (en) * 1999-05-19 2000-12-12 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
US20040063742A1 (en) * 2001-02-15 2004-04-01 Dan Peters Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
PT2260850T (pt) 2002-01-28 2018-10-24 Kyowa Hakko Kogyo Kk Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
CN100415217C (zh) * 2002-12-19 2008-09-03 先灵公司 腺苷A2a受体拮抗剂的应用
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CN101448498B (zh) 2006-05-16 2011-04-27 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) * 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20090246134A1 (en) * 2007-05-30 2009-10-01 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
CA2765876A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP3838271A1 (de) 2013-07-12 2021-06-23 Knopp Biosciences LLC Behandlung eines erhöhten spiegels von eosinophilen und/oder basophilen
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
WO2018170359A1 (en) * 2017-03-17 2018-09-20 University Of Virginia Patent Foundation Compositions and methods for treating peripheral nerve disease, disorders, and injuries
EP4083044A4 (de) * 2019-12-26 2024-03-27 Zhejiang Vimgreen Pharmaceuticals, Ltd Verwendung von triazolotriazin-derivaten zur behandlung von krankheiten

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
US5574060A (en) 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
FR2734264B1 (fr) 1995-05-19 1997-08-01 Lafon Labor Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
IL123583A (en) 1995-10-13 2003-07-31 Neurosearch As 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them
PL184843B1 (pl) 1995-11-02 2002-12-31 Neurosearch As Nowe skondensowane pochodne tropanu, sposób ich otrzymywania i zastosowanie oraz kompozycje farmaceutyczne
AU2388697A (en) * 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
AU4078397A (en) 1996-08-16 1998-03-06 Allelix Pharm-Eco, L.L.P. Slow-onset, long-lasting dopamine reuptake blockers
US5821386A (en) 1997-08-15 1998-10-13 Allelix-Pharm-Eco L.P. Compounds for treating ***e abuse
US6001330A (en) 1997-09-12 1999-12-14 Elmaleh; David R. Diagnostic and therapeutic alkylenediamine compounds and process
WO1999043678A1 (fr) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
WO1999053909A2 (en) * 1998-04-23 1999-10-28 Takeda Chemical Industries, Ltd. Pharmaceutical composition for neurotrophic action
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
AU2001259252A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Neuroprotective compositions

Also Published As

Publication number Publication date
WO2002080957A1 (en) 2002-10-17
US20040097540A1 (en) 2004-05-20
ATE424194T1 (de) 2009-03-15
EP1379269A1 (de) 2004-01-14
CA2440196A1 (en) 2002-10-17
US7160899B2 (en) 2007-01-09
JP2004529916A (ja) 2004-09-30
MXPA03009185A (es) 2004-02-17
EP1379269B1 (de) 2009-03-04

Similar Documents

Publication Publication Date Title
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
HK1083838A1 (en) A2a adenosine receptor antagonists
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
NZ522326A (en) Adenosine A2A receptor antagonists
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
PA8521501A1 (es) Ligandos para receptores de melanocortina
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
EA200400399A1 (ru) Способы лечения легочных заболеваний
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0000486A (pt) Antagonistas do neuropeptìdeo y
ATE260918T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
UY26207A1 (es) Antagonistas de los receptores de la il-8.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition